1-20 of 42
ketones
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients

Siham Abdelgani, Ahmed Khattab, John Adams, Mohamed Abu-Farha, Guisepe Daniele, Fahd Al-Mulla, Stefano Del Prato, Ralph A. DeFronzo, Muhammad Abdul-Ghani
Journal: Diabetes Care
Diabetes Care 2023;46(5):978–984
DOI: https://doi.org/10.2337/dc22-0885
Published: 01 March 2023
View article titled, Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients
Open the PDF for Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients in another window
Journal Articles

Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial

Melissa-Rosina Pasqua, Adnan Jafar, Alessandra Kobayati, Michael A. Tsoukas, Ahmad Haidar
Journal: Diabetes Care
Diabetes Care 2023;46(1):165–172
DOI: https://doi.org/10.2337/dc22-0490
Published: 10 November 2022
View article titled, Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial
Open the PDF for Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial in another window
Journal Articles

The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes

Roselle A. Herring, Fariba Shojaee-Moradie, Mary Stevenage, Iain Parsons, Nicola Jackson, Jeewaka Mendis, Benita Middleton, A. Margot Umpleby, Barbara A. Fielding, Melanie Davies, David L. Russell-Jones
Journal: Diabetes Care
Diabetes Care 2022;45(6):1408–1415
DOI: https://doi.org/10.2337/dc21-2043
Published: 21 March 2022
View article titled, The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes
Open the PDF for The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes in another window
Journal Articles

Erratum. Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis. Diabetes Care 2022;45:267–272

Eric S. Kilpatrick, Alexandra E. Butler, Linda Ostlundh, Stephen L. Atkin, David B. Sacks
Journal: Diabetes Care
Diabetes Care 2022;45(6):1490
DOI: https://doi.org/10.2337/dc22-er06a
Published: 03 March 2022
View article titled, Erratum. Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis. Diabetes Care 2022;45:267–272
Open the PDF for Erratum. Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis. Diabetes Care 2022;45:267–272 in another window
Journal Articles

Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis

Eric S. Kilpatrick, Alexandra E. Butler, Linda Ostlundh, Stephen L. Atkin, David B. Sacks
Journal: Diabetes Care
Diabetes Care 2022;45(2):267–272
DOI: https://doi.org/10.2337/dc21-2279
Published: 17 January 2022
View article titled, Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis
Open the PDF for Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis in another window
Journal Articles

Response to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126

Peter S. Hamblin, Rosemary Wong, Elif I. Ekinci, Shoshana Sztal-Mazer, Shananthan Balachandran, Aviva Frydman, Timothy P. Hanrahan, Raymond Hu, Shara N. Ket, Alan Moss, Mark Ng, Sashikala Ragunathan, Leon A. Bach
Journal: Diabetes Care
Diabetes Care 2022;45(1):e17–e18
DOI: https://doi.org/10.2337/dci21-0048
Published: 28 December 2021
View article titled, Response to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126
Open the PDF for Response to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126 in another window
Journal Articles

Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126

Venkatesan Thiruvenkatarajan, Emily J. Meyer, David Jesudason
Journal: Diabetes Care
Diabetes Care 2022;45(1):e15–e16
DOI: https://doi.org/10.2337/dc21-1413
Published: 28 December 2021
View article titled, Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126
Open the PDF for Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes. Diabetes Care 2021;44:e124–e126 in another window
Journal Articles

A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes

Barbora Paldus, Dale Morrison, Dessi P. Zaharieva, Melissa H. Lee, Hannah Jones, Varuni Obeyesekere, Jean Lu, Sara Vogrin, André La Gerche, Sybil A. McAuley, Richard J. MacIsaac, Alicia J. Jenkins, Glenn M. Ward, Peter Colman, Carmel E.M. Smart, Rowen Seckold, Bruce R. King, Michael C. Riddell, David N. O’Neal
Journal: Diabetes Care
Diabetes Care 2022;45(1):194–203
DOI: https://doi.org/10.2337/dc21-1593
Published: 17 November 2021
View article titled, A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes
Open the PDF for A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes in another window
Journal Articles

Erratum. Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk? Diabetes Care 2021;44: 280–289

Helen L. Tanner, Marloes Dekker Nitert, Leonie K. Callaway, Helen L. Barrett
Journal: Diabetes Care
Diabetes Care 2021;44(6):1456
DOI: https://doi.org/10.2337/dc21-er06b
Published: 18 June 2021
View article titled, Erratum. Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk? Diabetes Care 2021;44: 280–289
Open the PDF for Erratum. Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk? Diabetes Care 2021;44: 280–289 in another window
Journal Articles

Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes

Peter S. Hamblin, Rosemary Wong, Elif I. Ekinci, Shoshana Sztal-Mazer, Shananthan Balachandran, Aviva Frydman, Timothy P. Hanrahan, Raymond Hu, Shara N. Ket, Alan Moss, Mark Ng, Sashikala Ragunathan, Leon A. Bach
Journal: Diabetes Care
Diabetes Care 2021;44(6):e124–e126
DOI: https://doi.org/10.2337/dc21-0256
Published: 25 April 2021
View article titled, Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes
Open the PDF for Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitor–Treated Type 2 Diabetes in another window
Journal Articles

Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk?

Helen L. Tanner, Marloes Dekker Nitert, Leonie K. Callaway, Helen L. Barrett
Journal: Diabetes Care
Diabetes Care 2021;44(1):280–289
DOI: https://doi.org/10.2337/dc20-2008
Published: 14 December 2020
View article titled, Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk?
Open the PDF for Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk? in another window
Journal Articles

Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes

Roselle A. Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, A. Margot Umpleby, Melanie Davies, David L. Russell-Jones
Journal: Diabetes Care
Diabetes Care 2020;43(9):2128–2136
DOI: https://doi.org/10.2337/dc19-2579
Published: 08 July 2020
View article titled, Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes
Open the PDF for Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes in another window
Journal Articles

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Thomas Danne, Satish Garg, Anne L. Peters, John B. Buse, Chantal Mathieu, Jeremy H. Pettus, Charles M. Alexander, Tadej Battelino, F. Javier Ampudia-Blasco, Bruce W. Bode, Bertrand Cariou, Kelly L. Close, Paresh Dandona, Sanjoy Dutta, Ele Ferrannini, Spiros Fourlanos, George Grunberger, Simon R. Heller, Robert R. Henry, Martin J. Kurian, Jake A. Kushner, Tal Oron, Christopher G. Parkin, Thomas R. Pieber, Helena W. Rodbard, Desmond Schatz, Jay S. Skyler, William V. Tamborlane, Koutaro Yokote, Moshe Phillip
Journal: Diabetes Care
Diabetes Care 2019;42(6):1147–1154
DOI: https://doi.org/10.2337/dc18-2316
Published: 06 February 2019
View article titled, International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors
Open the PDF for International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors in another window
Includes: Supplementary data
Journal Articles

John Denis McGarry, PhD: A Remembrance of a Master Metabolic Physiologist

Christopher B. Newgard
Journal: Diabetes Care
Diabetes Care 2018;41(7):1330–1336
DOI: https://doi.org/10.2337/dci18-0022
Published: 14 June 2018
View article titled, John Denis McGarry, PhD: A Remembrance of a Master Metabolic Physiologist
Open the PDF for John Denis McGarry, PhD: A Remembrance of a Master Metabolic Physiologist in another window
Journal Articles

Renal Handling of Ketones in Response to Sodium–Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes

Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Elisabetta Barsotti, Aldo Clerico, Elza Muscelli
Journal: Diabetes Care
Diabetes Care 2017;40(6):771–776
DOI: https://doi.org/10.2337/dc16-2724
Published: 21 March 2017
View article titled, Renal Handling of Ketones in Response to Sodium–Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes
Open the PDF for Renal Handling of Ketones in Response to Sodium–Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Poor Adherence to Ketone Testing in Patients With Type 1 Diabetes

Anastasia Albanese-O’Neill, Mengdi Wu, Kellee M. Miller, Laura Jacobsen, Michael J. Haller, Desmond Schatz
Journal: Diabetes Care
Diabetes Care 2017;40(4):e38–e39
DOI: https://doi.org/10.2337/dc16-2620
Published: 18 January 2017
View article titled, Poor Adherence to Ketone Testing in Patients With Type 1 Diabetes
Open the PDF for Poor Adherence to Ketone Testing in Patients With Type 1 Diabetes in another window
Journal Articles

Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114

Ele Ferrannini, Michael Mark, Eric Mayoux
Journal: Diabetes Care
Diabetes Care 2016;39(12):e226
DOI: https://doi.org/10.2337/dci16-0033
Published: 10 November 2016
View article titled, Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114
Open the PDF for Response to Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114 in another window
Journal Articles

Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114

Jens Jordan, Ali El-Armouche, Markolf Hanefeld, Stefan R. Bornstein, Andreas L. Birkenfeld
Journal: Diabetes Care
Diabetes Care 2016;39(12):e224–e225
DOI: https://doi.org/10.2337/dc16-1588
Published: 10 November 2016
View article titled, Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114
Open the PDF for Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114 in another window
Journal Articles

Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes

Giuseppe Daniele, Juan Xiong, Carolina Solis-Herrera, Aurora Merovci, Roy Eldor, Devjit Tripathy, Ralph A. DeFronzo, Luke Norton, Muhammad Abdul-Ghani
Journal: Diabetes Care
Diabetes Care 2016;39(11):2036–2041
DOI: https://doi.org/10.2337/dc15-2688
Published: 25 August 2016
View article titled, Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Open the PDF for Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes in another window
Journal Articles

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

Sunder Mudaliar, Sindura Alloju, Robert R. Henry
Journal: Diabetes Care
Diabetes Care 2016;39(7):1115–1122
DOI: https://doi.org/10.2337/dc16-0542
Published: 11 June 2016
View article titled, Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Open the PDF for Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis in another window